Subscribe to RSS
Download PDF
DOI: 10.1055/a-1336-2505
Staging esophageal cancer: low EUS accuracy in t2n0 patients
Abstract
Background and study aims Esophageal cancer (EC) is one of the most lethal malignancies worldwide. Staging of EC is performed with computed tomography (CT), positron-emission tomography (PET), and endoscopic ultrasonography (EUS). Patient management mostly depends on lymph node status. Compared to histopathology, the accuracy of EUS for T and N parameters is about 85 % and 75 %, respectively. Errors in staging may change prognosis. The aim of this study was to assess the role of EUS in T2-N0 EC considering the experience of two high-volume digestive endoscopic centers.
Methods Two prospectively collected databases were queried to identify all patients with EC, staged as cT2N0 by EUS, with no distant metastases at CT/PET scan and who underwent transthoracic esophagectomy. Preoperative EUS staging (cTNM) was compared to histopathology of the surgical specimen (pTNM) to evaluate accuracy.
Results Of 729 consecutive patients with EC between January 2011 and September 2018, 72 (49 men) had cT2N0 disease. CT and PET scans confirmed the absence of distant metastasis. In 43 of 72 patients (60 %), the evaluation was correct, 23 of 72 (31,7 %) were understaged, and six of 72 patients (8,3 %) were overstaged. Among the understaged patients, eight were understaged by tumor depth (35 %), seven by nodal involvement (30 %), and eight by both (35 %). All six patients who were overstaged had T1b-N0 disease. EUS accuracy was 77 % in staging for tumor depth and 82 % in staging for nodal metastases. The positive predictive value (PPV) for cT2N0 EC was 60 % (43 pT2N0 /72 cT2N).
Conclusions The accuracy of EUS staging of T2N0 EC is low, with only 60 % of patients undergoing appropriate therapy based on histopathology.
Publication History
Received: 18 June 2020
Accepted: 14 October 2020
Article published online:
18 February 2021
© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Jemal A, Siegel R, Xu J. et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300
- 2 Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003; 349: 2241-2252
- 3 Visbal AL, Allen MS, Miller DL. et al. Ivor Lewis esophagogastrectomy for esophageal cancer. Ann Thorac Surg 2001; 71: 1803-1808
- 4 Low DE, Kunz S, Schembre D. et al. Esophagectomy: itʼs not just about mortality anymore: standardized perioperative clinical pathways improve outcomes in patients with esophageal cancer. J Gastrointest Surg 2007; 11: 1395-1402 discussion 1402.
- 5 van Hagen P, Hulshof MC, van Lanschot JJ. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084
- 6 Mariette C, Dahan L, Mornex F. et al. Surgery alone vs chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial. J Clin Oncol 2014; 32: 2416-2422
- 7 Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol 2010; 17: 1721-1724
- 8 Rice TW, Rusch VW, Ishwaran H. et al. Worldwide Esophageal Cancer Collaboration. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/ International Union Against Cancer Cancer Staging Manuals. Cancer 2010; 116: 3763-3773
- 9 Rice TW, Blackstone EH, Rusch VW. A cancer staging primer: esophagus and esophagogastric junction. J Thorac Cardiovasc Surg 2010; 1 39: 527-529
- 10 Byrne MF, Jowell PS. Gastrointestinal imaging: endoscopic ultrasound. Gastroenterology 2002; 122: 1631-1648
- 11 Faigel DO, Deveney C, Phillips D. et al. Biopsy-negative malignant esophageal stricture: diagnosis by endoscopic ultrasound. Am J Gastroenterol 1998; 93: 2257-2260
- 12 Provenzale D, Schmitt C, Wong JB. Barrettʼs esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94: 2043-2053
- 13 Rice TW, Rusch VW, Apperson-Hansen C. et al. Worldwide esophageal cancer collaboration. Dis Esophagus 2009; 22: 1-8
- 14 Vazquez-Sequeiros E, Norton ID, Clain JE. et al. Impact of EUS-guided fine-ne edle aspiration on lymph node staging in patients with esophageal carcinoma. Gastrointest Endosc 2001; 53: 751-757
- 15 Puli SR, Reddy JBK, Bechtold ML. et al. Staging accuracy of esophageal cancer by endoscopic ultrasound: A meta-analysis and systematic review. World J Gastroenterol 2008; 14: 1479-1490
- 16 Kelly S, Harris KM, Berry E. et al. A systematic review of the staging performance of endoscopic ultrasound in gastro-oesophageal carcinoma. Gut 2001; 49: 534-910
- 17 Luu C, Amaral M, Klapman J. et al. Endoscopic ultrasound staging for early esophageal cancer: Are we denying patients neoadjuvant chemo-radiation?. World J Gastroenterol 2017; 23: 8193-8199
- 18 Puli MF, Sivak Jr MV , Rice T. et al. Endosonographic features predictive of lymph node metastasis. Gastrointest Endosc 1994; 40: 442
- 19 Lehr L, Rupp N, Siewert JR. Assessment of resectability of esophageal cancer by computed tomography and magnetic resonance imaging. Surgery 1988; 103: 344-350
- 20 Pfau PR, Perlman SB, Stanko P. et al. The role and clinical value of EUS in a multimodality esophageal carcinoma staging program with CT and positron emission tomography. Gastrointest Endosc 2007; 65: 377-384
- 21 Young PE, Gentry AB, Acosta RD. et al. Endoscopic ultrasound does not accurately stage early adenocarcinoma or high-grade dysplasia of the esophagus. Cl Gastroenterol Hepatol 2010; 8: 1037-1041
- 22 Sjoquist KM, Burmeister BH, Smithers BM. et al. Australasian Gastro-Intestinal Trials Group. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12: 681-692
- 23 Cho JW, Choi SC, Jang JY. Korean ESD Study Group.. et al. Lymph node metastases in esophageal carcinoma: an endoscopistʼs view. Clin Endosc 2014; 47: 523-526
- 24 Urschel JD, Vasan H, Blewett CJ. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2002; 183: 274-279
- 25 Dhungel B, Diggs BS, Hunter JG. et al. Patient and peri-operative predictors of morbidity and mortality after esophagectomy: American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP), 2005-2008. J Gastrointest Surg 2010; 14: 1492-1501
- 26 Merritt RE, Whyte RI, DʼArcy NT. et al. Morbidity and mortality after esophagectomy following neoadjuvant chemoradiation. Ann Thorac Surg 2011; 92: 2034-2040
- 27 Shah PM, Gerdes H. Endoscopic options for early stage esophageal cancer. J Gastrointest Oncol 2015; 6: 20-3028
- 28 Tekola BD, Sauer BG, Wang AY. et al. Accuracy of endoscopic ultrasound in the diagnosis of T2N0 esophageal cancer. J Gastrointest Cancer 2014; 45: 342-346
- 29 Pech O, Günter E, Dusemund F. et al. Accuracy of endoscopic ultrasound in preoperative staging of esophageal cancer: results from a referral center for early esophageal cancer. Endoscopy 2010; 42: 456-461
- 30 Hardacker TJ, Ceppa D, Okereke I. et al. Treatment of Clinical T2N0M0 Esophageal cancer. Ann Surg Oncol 2014; 21: 3739-3743
- 31 Gabriel E, Attwood K, Du W. et al. Association between clinically staged node-negative esophageal adenocarcinoma and overall survival benefit from neoadjuvant chemoradiation. JAMA Surg 2016; 151: 234-245
- 32 Vining P, Birdas TJ. Management of clinical T2N0 esophageal cancer: a review. J Thorac Dis 2019; 11: S1629-S1633